Miller has reviewed and conducted interviews with leading scientists in America who are investigating the effects on humans of psychedelic medicines such as LSD, MDMA, also known as ecstasy, Psilocybin, also known as magic mushrooms, and Ayahuasca. His first experience with psychedelics began in 1966 when he was teaching psychology at the University of Michigan in Ann Arbor. It was then he began research into what science had to say about these medicines and why the United States government declared them non grata to the extent that profoundly obstructs scientific research into them. However, against all odds, research has persisted revealing that certain psychedelic medicines administered by proper protocol, have shown that altered states of consciousness can facilitate creativity and psychophysical healing. Respected researchers such as Rick Doblin, Ph.D., the founder of MAPS, which stands for Multidisciplinary Association for Psychedelic Studies, has as his professional goal to develop the legal context for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people. It’s his hope that this will eventually lead psychedelics to become legal for use by licensed psychedelic therapists. Roland Griffiths, Ph.D., Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine demonstrated to the world that one session with Psilocybin is effective for a year later for depression. These research studies are suggesting new avenues for treatment for many of our most debilitating illnesses, such as depression, anxiety, addiction, post-traumatic stress disorder, OCD, and others. Our guest, Richard Miller, will talk about the scientific research that has been going on to better understand the emergence of psychedelic psychotherapy.
